A PON for All Seasons: Comparing Paraoxonase Enzyme Substrates, Activity and Action Including the Role of PON3 in Health and Disease

Overview

Journal Antioxidants (Basel)

Date 2022 Mar 25

PMID 35326240

Authors

Chrysan J Mohammed

Sabitri Lamichhane

Jacob A Connolly

Sophia M Soehnlen

Fatimah K Khalaf

Deepak Malhotra

Steven T Haller

Dragan Isailovic

David J Kennedy

Affiliations

Soon will be listed here.

Abstract

Paraoxonases (PONs) are a family of hydrolytic enzymes consisting of three members, PON1, PON2, and PON3, located on human chromosome 7. Identifying the physiological substrates of these enzymes is necessary for the elucidation of their biological roles and to establish their applications in the biomedical field. PON substrates are classified as organophosphates, aryl esters, and lactones based on their structure. While the established native physiological activity of PONs is its lactonase activity, the enzymes' exact physiological substrates continue to be elucidated. All three PONs have antioxidant potential and play an important anti-atherosclerotic role in several diseases including cardiovascular diseases. PON3 is the last member of the family to be discovered and is also the least studied of the three genes. Unlike the other isoforms that have been reviewed extensively, there is a paucity of knowledge regarding PON3. Thus, the current review focuses on PON3 and summarizes the PON substrates, specific activities, kinetic parameters, and their association with cardiovascular as well as other diseases such as HIV and cancer.

Citing Articles

PON-1 and PON-2 Polymorphisms and PON-1 Paraoxonase Activity in People Living with HIV-1.

Reichert C, Levy D, Maselli L, da Cunha J, Gualandro S, Bydlowski S Antioxidants (Basel). 2025; 14(2).

PMID: 40002395 PMC: 11851513. DOI: 10.3390/antiox14020209.

Plasma biomarkers in patients with age-related sarcopenia: a proteomic exploration and experimental validation.

Lin Q, Li K, Li L, Guan L, Zeng Y, Cai D Aging Clin Exp Res. 2024; 37(1):13.

PMID: 39725826 PMC: 11671435. DOI: 10.1007/s40520-024-02903-7.

The Analysis of Plasma Proteomics for Luminal A Breast Cancer.

Zhao M, Jiang Y, Kong X, Liu Y, Gao P, Li M Cancer Med. 2024; 13(23):e70470.

PMID: 39641443 PMC: 11622152. DOI: 10.1002/cam4.70470.

A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease.

Sharma A, Lee H Antioxidants (Basel). 2024; 13(11).

PMID: 39594531 PMC: 11590959. DOI: 10.3390/antiox13111389.

The Molecular Bases of Anti-Oxidative and Anti-Inflammatory Properties of Paraoxonase 1.

Jakubowski H Antioxidants (Basel). 2024; 13(11).

PMID: 39594433 PMC: 11591180. DOI: 10.3390/antiox13111292.

References

Jin Y, Li Q, Qiu J, Zhao X, Zheng C, Lv S . Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis. Tumour Biol. 2016; 37(10):14193-14203. DOI: 10.1007/s13277-016-5247-z. View

Teiber J, Horke S, Haines D, Chowdhary P, Xiao J, Kramer G . Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun. 2008; 76(6):2512-9. PMC: 2423076. DOI: 10.1128/IAI.01606-07. View

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R . Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004; 11(5):412-9. DOI: 10.1038/nsmb767. View

Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy M . Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013; 2(2):e000104. PMC: 3647254. DOI: 10.1161/JAHA.112.000104. View

Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik D . Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A. 2003; 101(2):482-7. PMC: 327173. DOI: 10.1073/pnas.2536901100. View

Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kroller-Schon S . New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. Int J Mol Sci. 2019; 20(1). PMC: 6337296. DOI: 10.3390/ijms20010187. View

Agrawal S, Agrawal N, Garg J, Mohandas R, Gupta T, Segal M . Heart failure and chronic kidney disease: should we use spironolactone?. Am J Med Sci. 2015; 350(2):147-51. DOI: 10.1097/MAJ.0000000000000514. View

She Z, Zheng W, Wei Y, Chen H, Wang A, Li H . Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009; 104(10):1160-8. DOI: 10.1161/CIRCRESAHA.108.192229. View

Sorenson R, Teiber J, La Du B . The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996; 33(3):498-507. DOI: 10.1006/geno.1996.0225. View

10.

Teiber J, Draganov D, La Du B . Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol. 2003; 66(6):887-96. DOI: 10.1016/s0006-2952(03)00401-5. View

11.

Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L . Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48(2):261-8. View

12.

Mohammed C, Xie Y, Brewster P, Ghosh S, Dube P, Sarsour T . Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease. J Clin Med. 2019; 8(7). PMC: 6678354. DOI: 10.3390/jcm8071034. View

13.

Khersonsky O, Rosenblat M, Toker L, Yacobson S, Hugenmatter A, Silman I . Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization. Biochemistry. 2009; 48(28):6644-54. DOI: 10.1021/bi900583y. View

14.

Xu S, Ilyas I, Little P, Li H, Kamato D, Zheng X . Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021; 73(3):924-967. DOI: 10.1124/pharmrev.120.000096. View

15.

Muthukrishnan S, Shete V, Sanan T, Vyas S, Oottikkal S, Porter L . Mechanistic Insights into the Hydrolysis of Organophosphorus Compounds by Paraoxonase-1: Exploring the Limits of Substrate Tolerance in a Promiscuous Enzyme. J Phys Org Chem. 2013; 25(12):1247-1260. PMC: 3740977. DOI: 10.1002/poc.3002. View

16.

Arenas M, Rodriguez E, Sahebkar A, Sabater S, Rizo D, Pallise O . Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018; 127:6-14. DOI: 10.1016/j.critrevonc.2018.04.005. View

17.

Shih D, Yu J, Vergnes L, Dali-Youcef N, Champion M, Devarajan A . PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis. FASEB J. 2014; 29(4):1185-97. PMC: 4396607. DOI: 10.1096/fj.14-260570. View

18.

Litvinov D, Mahini H, Garelnabi M . Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012; 4(11):523-32. PMC: 3503369. DOI: 10.4103/1947-2714.103310. View

19.

Khersonsky O, Tawfik D . Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005; 44(16):6371-82. DOI: 10.1021/bi047440d. View

20.

Camps J, Marsillach J, Joven J . The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009; 46(2):83-106. DOI: 10.1080/10408360802610878. View